David M. Berman
Alnylam Pharmaceuticals (United States)(US)Queen's University(CA)Brown University(US)Sinclair Pharma(GB)Cancer Genetics (United States)(US)Kingston Health Sciences Centre(CA)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, Urinary and Genital Oncology Studies, CAR-T cell therapy research
Most-Cited Works
- → Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma(2015)2,105 cited
- → Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma(2005)1,619 cited
- → Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours(2003)1,253 cited
- → Tissue repair and stem cell renewal in carcinogenesis(2004)1,202 cited
- → A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing(2007)1,126 cited
- → Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer(2003)1,082 cited